Your website may be one of your biggest regulatory vulnerabilities. The U.S. Food and Drug Administration (FDA) is actively reviewing healthcare companies' digital presences and issuing formal Warning Letters for violations identified directly on public-facing website pages.

For telehealth companies, medical spas, aesthetic practices, and weight-loss clinics offering compounded medications—particularly GLP-1 treatments—marketing claims carry substantial legal and regulatory weight.

Common Web Marketing Violations Triggering FDA Scrutiny

Regulatory agencies are paying close attention to public representations regarding compounded drugs. Some of the most common statements and visual choices attracting federal enforcement include:

• Misleading Product Terminology: Describing compounded GLP-1 formulations as “generic” versions of brand-name, FDA-approved drugs.

• Equivalency Claims: Suggesting compounded products are the “same as” or direct bioequivalent replacements for FDA-approved medications.

• Implied Approval: Using language or phrasing that implies compounded drugs have been directly evaluated or approved by the FDA for safety and effectiveness.

• Efficacy Representations: Stating that compounded products are “clinically proven” to achieve identical health or cosmetic outcomes to FDA-approved brand drugs.

• Deceptive Imagery: Utilizing product packaging imagery or graphics that obscure who actually compounded the medication, creating a misleading impression for consumers.

These are not obscure statements buried deep within regulatory filings. They are the exact phrases, taglines, and marketing claims routinely deployed on landing pages, social media campaigns, paid search ads, and patient intake portals.

Protecting Your Healthcare Brand Before Regulators Intervene

Marketing and growth teams often draft website copy designed to convert patients without realizing that certain terminology creates immediate regulatory exposure. For healthcare businesses providing compounded medications, compliance reviews can no longer stop at clinical workflows or pharmacy agreements—public marketing must face the same level of legal oversight.

The FDA and state authorities treat public digital content as direct evidence of business practice. Identifying and correcting misleading marketing claims proactively is significantly less costly and disruptive than responding to a formal FDA Warning Letter or state regulatory inquiry.

At MDRXLaw, we offer targeted compliance reviews of websites and digital marketing channels for healthcare businesses, medspas, and telehealth platforms offering compounded medications. We audit patient-facing representations, landing page content, paid advertising, social media posts, and pharmacy disclosure messaging to identify and resolve compliance risks before regulators intervene.

To schedule a website compliance review for your healthcare business, contact our legal team by phone at 212.668.0200 or via email at info@mdrxlaw.com.